JPRN-UMIN000008629已完成2 期
Phase II trial of palonosetron, aprepitant plus dexamethasone in the prevention of nausea and vomiting induced by chemotherapy for urothelial cancer. - Phase II trial of palonosetron, aprepitant plus dexamethasone in the prevention of nausea and vomiting induced by chemotherapy for urothelial cancer.
rology, Department of Medicine Kitasato University, School of Medicine0 个研究点目标入组 45 人开始时间: 2012年8月6日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 45
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Patients who need anticonvulsants therapy 2) Vomiting, or CTCAE grade 2 or higher nausea 3) History of hypersensitivity for Palonosetron and/or Aprepitant and/or Dexamethasone 4) Pregnant or lactating women or women of childbearing potential 5) Receiving medicine that has antiemetic activity 6) Patient who doesn't have ability or intention that cooperates for procedure of the study 7) Not appropriate for the study at the physician's assessment
研究者
相似试验
已完成
2 期
Phase II trial of palonosetron, aprepitant plus dexamethasone in the prevention of nausea and vomiting induced by hepatic arterial injection chemotherapy with cisplatin for Hepatocellular carcinomaHepatocellular carcinomaJPRN-UMIN000007265Gastroenterology, Department of Medicine Kitasato University, School of Medicine45
已完成
2 期
Randomized Phase II trial of palonosetron, aprepitant plus dexamethasone for 1 day with or without dexamethasone on days 2 and 3 in the prevention of nausea and vomiting induced by chemotherapy for breast cancerbreast cancerJPRN-UMIN000006977Kitasato University School of Medicine Department of Surgery80
已完成
2 期
A phase II trial of aprepitant, palonosetron, dexamethasone and olanzapine for the prevention of cisplatin-based chemotherapy-induced nausea and vomiting for gynecological cancer.gynecological cancerJPRN-UMIN000011857Kansai Clinical Oncology Group (KCOG)40
进行中（未招募）
不适用
Phase II study with Palonosetron alone in preventing chemotherapy-induced nausea and vomiting in untreated patients with aggressive Non Hodgkin?s Lymphomas who underwent moderately emetogenic chemotherapy - Palonosetron in NHpreventing chemotherapy-induced nausea and vomiting in untreated patients with aggressive Non Hodgkin?s Lymphomas who underwent moderately emetogenic chemotherapy.MedDRA version: 9.1Level: HLTClassification code 10028817Term: Nausea and vomiting symptomsEUCTR2006-003189-33-ITG.I.S.L. - GRUPPO ITALIANO STUDIO LINFOMI
已完成
3 期
A randomized phase III trial of palonosetron versus palonosetron plus dexamethasone (day1) for the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy (HOPE-02)Colorectal CancerJPRN-UMIN000013249HOPE group(Hokkaido Supportive Care Oncology Project - an Expert Group Initiative)320